Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics

Teva Pharmaceutical Industries Ltd. ADR (TEVA): $8.47

0.16 (+1.93%)

POWR Rating

Component Grades














  • TEVA scores best on the Value dimension, with a Value rank ahead of 99.14% of US stocks.
  • TEVA's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • TEVA's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

TEVA Stock Summary

  • In terms of twelve month growth in earnings before interest and taxes, Teva Pharmaceutical Industries Ltd is reporting a growth rate of -150.72%; that's higher than merely 12.54% of US stocks.
  • As for revenue growth, note that TEVA's revenue has grown -4.69% over the past 12 months; that beats the revenue growth of only 13.73% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TEVA comes in at 22.28% -- higher than that of 92.16% of stocks in our set.
  • Stocks that are quantitatively similar to TEVA, based on their financial statements, market capitalization, and price volatility, are CAE, OCDX, BDC, CW, and VTRS.
  • TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to

TEVA Valuation Summary

  • TEVA's EV/EBIT ratio is -11.9; this is 140.61% lower than that of the median Healthcare stock.
  • Over the past 227 months, TEVA's price/earnings ratio has gone down 27.
  • TEVA's price/earnings ratio has moved down 27 over the prior 227 months.

Below are key valuation metrics over time for TEVA.

Stock Date P/S P/B P/E EV/EBIT
TEVA 2021-08-31 0.6 1 -2.7 -11.9
TEVA 2021-08-30 0.6 1 -2.6 -11.9
TEVA 2021-08-27 0.6 1 -2.6 -11.9
TEVA 2021-08-26 0.6 1 -2.6 -11.9
TEVA 2021-08-25 0.6 1 -2.7 -12.0
TEVA 2021-08-24 0.6 1 -2.7 -12.0

TEVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TEVA has a Quality Grade of C, ranking ahead of 57.93% of graded US stocks.
  • TEVA's asset turnover comes in at 0.33 -- ranking 140th of 682 Pharmaceutical Products stocks.
  • LFVN, ONVO, and ANAB are the stocks whose asset turnover ratios are most correlated with TEVA.

The table below shows TEVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.330 0.468 0.064
2021-06-30 0.329 0.469 -0.088
2021-03-31 0.319 0.463 -0.097
2020-12-31 0.316 0.464 -0.102
2020-09-30 0.298 0.471 -0.108
2020-06-30 0.293 0.462 0.018

TEVA Stock Price Chart Interactive Chart >

Price chart for TEVA

TEVA Price/Volume Stats

Current price $8.47 52-week high $11.55
Prev. close $8.31 52-week low $7.23
Day low $8.19 Volume 10,512,000
Day high $8.52 Avg. volume 8,999,519
50-day MA $8.74 Dividend yield N/A
200-day MA $8.88 Market Cap 9.35B

Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio

Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.

TEVA Latest News Stream

Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream

Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about Teva Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Teva Pharmaceutical: Prepare For Takeoff

No summary available.

Seeking Alpha | February 16, 2022

Top Stock Reports for Apple, Walt Disney & Broadcom

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), The Walt Disney Company (DIS), and Broadcom Inc. (AVGO).

Yahoo | February 16, 2022

Warren Buffett Stocks: This Is What Berkshire Hathaway Bought And Sold In Q4

The post Warren Buffett Stocks: This Is What Berkshire Hathaway Bought And Sold In Q4 appeared on . Warren Buffett’s Berkshire Hathaway (BRKB) bought beaten-down Activision Blizzard (ATVI) and Nu Holdings (NU) for the first time in the fourth quarter of 2021, while exiting Teva Pharmaceuticals (TEVA) and…

Bitcoin Ethereum News | February 15, 2022

Buffett’s Berkshire Takes Activision Blizzard Stake, Exits Teva

(Bloomberg) -- Warren Buffett’s Berkshire Hathaway Inc. took a stake in Activision Blizzard Inc., the game giant that has agreed to be acquired by Microsoft Corp., in an investment that would have been valued at $975 million at the end of the year. Most Read from BloombergHere’s What the Pandemic Has in Store for the World NextPutin Signals Talks With U.S. to Go On as Some Drills EndRussia Says Some Troops Are Returning to Base After DrillsStocks Fail to Hold Gains as Treasury Yields Jump: Marke

Yahoo | February 14, 2022

Teva Pharmaceutical Industries Limited 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 11, 2022

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo -9.70%
3-mo 3.93%
6-mo -3.20%
1-year -23.14%
3-year -26.60%
5-year -70.65%
YTD 5.74%
2021 -16.99%
2020 -1.53%
2019 -36.45%
2018 -18.63%
2017 -46.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4864 seconds.